Category Archives: Topics

Ionis Receives PRV; Modular Medical Signs Contract with US PBM

Two cardiometabolic-related news items have been observed: Ionis Pharmaceuticals received a PRV upon approval of Zanvastro in Alexander Disease (view press release), and Modular Medical contracted with an undisclosed US PBM for its Pivot tubeless patch pump (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

G&L and Menarini Bofanglutide Licensing Agreement; G&L FIH QW Oral GLP-1RA Study; Inventiva NATiV3 LPLV Milestone; Modular Medical Patch Pump Update; Eledon Tegoprubart Updates; Superluminal Series B Financing Round

A series of cardiometabolic-related news items has been observed from Menarini, Gan & Lee Pharmaceuticals, Inventiva, Modular Medical, Eledon Pharmaceuticals, and Superluminal Medicines. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Lilly Orfor Obesity/ORC Prevention Study; NewAmsterdam Alzheimer’s Study; Novartis to Advance IL-6 Inhibitor to Ph3; Wegovy Pill Germany Launch; Pfizer Berobenatide Japan Studies; MiniMed CY Q2 ’26 Earnings; Novo Initiates AMBITION 7

A series of cardiometabolic-related news items has been observed from Lilly, NewAmsterdam Pharma, Novartis, Novo Nordisk, Pfizer, MiniMed, and CSPC Pharmaceutical. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Ascletis Doses First Patient in Ph3; Arrowhead ESC 2026 Investor Event; Cytokinetics ACACIA-HCM Primary Results; Amgen Repatha Sub-Analyses; Alnylam Vutrisiran Sub-Analysis; Lilly 52-Week Taltz + Tirzepatide Data

A series of cardiometabolic-related news items has been observed from Ascletis Pharma, Arrowhead Pharmaceuticals, Cytokinetics, Amgen, Alnylam, and Lilly. Below, FENIX provides highlights and insights for the respective news items, including a projected approval timeline for Ph3 oral AOM development.

This content is for Read Less members only.
Already a member? Log in here

Innovent QW Oral Small Molecule GLP-1RA Study; Mounjaro CVRR Label Expansion; Pfizer China-Based Berobenatide Obesity Study

Three cardiometabolic-related news items have been observed: Innovent Biologics initiated a Ph1 FIH study of its QW oral small-molecule GLP-1RA (view CT.gov record); Lilly received FDA approval for Mounjaro’s CVRR label expansion based on the SURPASS-CVOT study (view press release); and Pfizer initiated a Ph3 berobenatide study in an obese Chinese population (view CT.gov record). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Gubra Receives Milestone Payment from AbbVie; Caliway Advances Lipolysis Drug

Two cardiometabolic-related news items have been observed: Gubra received a $50M milestone payment from AbbVie (view press release), and Caliway Biopharmaceuticals received IND clearance and IRB approval for its small molecule lipolysis drug (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Abbott’s Libre Duo Approved by FDA; AZ Initiates Pivotal Amylin Studies; New Lilly Medicare Obesity Ad; Lilly Initiates First Clazakizumab Study; Google Pixel Watch Non-Invasive Insulin Resistance; Revier Seed Financing for HFpEF and ASCVD; Haisco Partners with US-Based VC for Spinout

A series of cardiometabolic-related news items has been observed from Abbott, AstraZeneca, Lilly, Google, Revier Therapeutics, and Haisco Pharmaceutical. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here